- Home
- IMOS vs PHAR Comparison
IMOS vs PHAR Comparison
Compare IMOS & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMOS | PHAR |
|---|---|---|
| Founded | 1997 | 1988 |
| Country | Taiwan | Netherlands |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.5M | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IMOS | PHAR |
|---|---|---|
| Price | $27.94 | $16.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 24.1K | 22.9K |
| Earning Date | 11-11-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | 0.00 |
| Revenue | ★ $748,307,671.00 | $362,274,000.00 |
| Revenue This Year | $5.78 | $24.80 |
| Revenue Next Year | $10.84 | $6.84 |
| P/E Ratio | ★ $129.31 | $2,942.01 |
| Revenue Growth | N/A | ★ 26.78 |
| 52 Week Low | $12.78 | $7.50 |
| 52 Week High | $30.98 | $17.86 |
Technical Indicators
Market Signals| Indicator | IMOS | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 59.98 | 54.58 |
| Support Level | $27.55 | $15.76 |
| Resistance Level | $28.36 | $17.67 |
| Average True Range (ATR) | 0.89 | 0.79 |
| MACD | -0.26 | -0.08 |
| Stochastic Oscillator | 53.45 | 48.57 |
Price Performance
Historical ComparisonAbout IMOS ChipMOS TECHNOLOGIES INC.
ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.